- Licensing Agreements with partners in Europe and Asia to support local production, technology transfer, and portfolio growth across cardiovascular disease, diabetes and oncology in UAE, KSA and rest of the Middle East
Milan, Italy / United Arab Emirates, October: ADCAN Pharma, a UAE-based pharmaceutical manufacturer, signed five licensing and local manufacturing agreements and binding term sheets with international partners, at CPHI Milan 2026, the global pharmaceutical trade event held from 6–8 October 2026 in Milan.
The agreements and term sheets span cardiovascular disease, diabetes, and oncology, and are intended to support licensing, technology transfer, and local manufacturing partnerships. The company said the deals will help expand its product portfolio and strengthen pharmaceutical production in the UAE, KSA and rest of Middle East.
Dr Shaikha Al Mazrouei, Research and Studies Advisor at the Emirates Drug Establishment (EDE), said: “International partnerships in licensing, technology transfer and local manufacturing are an important enabler of the UAE’s pharmaceutical industry. At the Emirates Drug Establishment, we are committed to ensuring that this growth is supported by a regulatory environment that strengthens quality and compliance, enables innovation and knowledge transfer, and enhances the competitiveness of UAE-manufactured pharmaceutical products in regional and global markets.”
ADCAN Pharma said the agreements will also support its goal of producing critical medicines locally in the UAE, KSA and rest of Middle East, a development it described as an important step in building domestic manufacturing capacity and improving access to treatment across the region.
“These agreements reflect our focus on building long-term partnerships that can strengthen local manufacturing and expand access to essential medicines,” said Mr Hamdan Mohamed AlDahmani, Chairman of ADCAN Pharma. “Our priority is to support patient access, capability transfer, and the continued growth of the UAE and the region’s pharmaceutical sector.”
Dr Fokion Sinis, Chief Executive Officer of ADCAN Pharma, said the MOUs are part of the company’s broader localization strategy. “Through licensing and technology transfer, we aim to bring critical therapies closer to patients in the UAE while strengthening our capabilities across cardiovascular care, diabetes, and oncology across KSA and the Middle East” he said.
The partners include Elpen, Alvion, and Genepharm of Greece; Inventia of India; and Lotus of Taiwan.
The company said the Emirates Drug Establishment plays a key role in supporting the UAE’s industrial and healthcare priorities by advancing a regulatory environment that strengthens local pharmaceutical manufacturing, quality, compliance and innovation, while supporting the resilience of medicine supply chains. It added that this role complements national initiatives such as Made in the UAE and the expansion of local production, helping strengthen domestic manufacturing capacity, improve patient access, and reinforce the UAE’s position as a regional hub for pharmaceutical manufacturing and innovation.
